Announcements Trials

Browse Landscape

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Skin Neoplasms 2 Sezary Syndrome 2 Mycosis Fungoides 2 Lymphoma, T-Cell, Cutaneous 2 Lymphoma 2 Lymphoma, T-Cell 1

Interventions

romidepsin 12 Cyclophosphamide 11 Vincristine 9 Rituximab 9 Etoposide 9 Lenalidomide 8 Doxorubicin 8 Brentuximab Vedotin 8 fludarabine 6 Prednisone 6 Peripheral Blood Stem Cell Transplantation 6 Melphalan 6 Depsipeptides 6 fludarabine phosphate 5 Mycophenolic Acid 5 Lactones 5 Gemcitabine 5 Cytarabine 5 Bendamustine Hydrochloride 5 Antilymphocyte Serum 5 Whole-Body Irradiation 4 Tacrolimus 4 Sirolimus 4 Methotrexate 4 MLN 8237 4 Carmustine 4 Bortezomib 4 10-propargyl-10-deazaaminopterin 4 thymoglobulin 3 duvelisib 3

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

Completed × Lymphoma, T-Cell × zanolimumab × Clear all

NCT00877656 2024-03-18

HuMax-CD4 in Non-Cutaneous T-Cell Lymphoma

Emergent BioSolutions

Phase 2/3 Completed

Lymphoma, T-Cell

Data powered by HemOnc (CC BY 4.0) Colophon ⚡